Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365571 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3154207 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02365571 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 64 participants.
The verdict
NCT02365571, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on the body. There will be 3 parts to this study. Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for each participant. Each participant will receive two doses of LY3154207, if part A is completed. Part B will test a single dose of LY3154207 and will last approximately 5 weeks for each participant. Part B includes collecting fluid from the spinal column to measure levels of LY3154207. Part C will include a single dose of LY3154207 given alone and then a second dose given along with itraconazole to look for change in LY3154207 levels. Part C will last about 3 weeks for each participant. Participants may only enroll in 1 of the 3 parts of the study.
Interventions
- DRUG Placebo
- DRUG Itraconazole
- DRUG LY3154207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365571
The ClinicalTrials.gov registry entry for NCT02365571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02365571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365571 about?
NCT02365571 is a clinical study titled "A Study of LY3154207 in Healthy Participants". This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on the body. There will be 3 parts to this study. Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for each participant. Each participant will receive two doses of LY315...
What is the current status of trial NCT02365571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2015-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02365571?
The interventions under investigation include: Placebo (DRUG), Itraconazole (DRUG), LY3154207 (DRUG).
Who is sponsoring clinical trial NCT02365571?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.